Two pharma giants. Two completely different approaches to the same problem. Eli Lilly's triple agonist vs Novo Nordisk's amylin-GLP-1 combination — a deep comparison of the science, the trial data, and what each could mean for the future of obesity medicine.
The most fascinating thing about this rivalry is that both drugs are trying to solve the same problem — sustainable, significant weight loss — but through entirely different biological pathways. Neither is simply a more powerful version of semaglutide.
Retatrutide activates three distinct receptors simultaneously. GLP-1 suppresses appetite and slows digestion. GIP enhances the insulin response and may reduce GI side effects. The glucagon receptor — the key differentiator — increases energy expenditure and drives fat breakdown in the liver. The result is both reduced intake and increased burn.
CagriSema combines two drugs into a single injection. Semaglutide (2.4mg, the same dose as Wegovy) handles GLP-1 receptor agonism. Cagrilintide is a long-acting synthetic version of amylin — a pancreatic hormone that signals fullness and slows gastric emptying through a completely separate neural pathway. The two mechanisms are synergistic, each amplifying the other's appetite-suppressing effect.
This is where the comparison gets genuinely interesting — and where context matters enormously.
⚠ Phase 2 and Phase 3 data are not directly comparable. Retatrutide's Phase 3 numbers may differ from Phase 2. Comparisons across trials are indicative only.
The critical caveat: retatrutide's 24.2% figure comes from a 338-person Phase 2 trial over just 24 weeks. CagriSema's 22.7% comes from a much larger Phase 3 trial over 68 weeks. Phase 3 trials typically show more modest results than Phase 2 because the patient population is broader and the conditions more controlled. Retatrutide's Phase 3 data, when published, may land above or below its Phase 2 headline.
What we can say with confidence: both drugs represent a significant step above anything currently approved, and both comfortably clear the 20% weight loss threshold that many obesity specialists consider the benchmark for meaningful, durable results.
| Category | Retatrutide | CagriSema |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Receptors targeted | 3 (GLP-1, GIP, Glucagon) | 2 (GLP-1, Amylin) |
| Best weight loss result | 24.2% (Phase 2, 24 wks) | 22.7% (Phase 3, 68 wks) |
| Trial data maturity | Phase 3 ongoing | Phase 3 complete (REDEFINE 1) |
| Expected approval | 2027–2028 | 2026–2027 (earlier) |
| Liver disease (MASH) | Strong — glucagon pathway directly targets liver fat | Less data available |
| Energy expenditure boost | Yes — glucagon receptor increases calorie burn | Not a primary mechanism |
| GI tolerability | Similar to GLP-1 class — ~42% nausea at max dose | Similar profile reported |
| Type 2 diabetes indication | Yes — TRIUMPH-T2D trial active | Yes — REDEFINE 2 trial active |
| Company GLP-1 experience | Strong (Mounjaro, Zepbound) | Extensive (Ozempic, Wegovy, Victoza) |
| Novel mechanism | Glucagon agonism — new to approved drugs | Amylin analogue — new to approved drugs |
CagriSema has a meaningful head start on the regulatory path, largely because semaglutide — one of its two components — already has an extensive FDA-approved safety record. Novo Nordisk is essentially filing for a new formulation of a known compound combined with a novel one.
This is arguably where retatrutide has its clearest advantage. Metabolic dysfunction-associated steatohepatitis (MASH) — formerly known as NASH — involves fat accumulation in the liver, and the glucagon receptor plays a direct role in hepatic fat metabolism. Glucagon receptor agonism stimulates fat breakdown in the liver through a mechanism that GLP-1 and amylin don't directly target.
Eli Lilly has dedicated a specific TRIUMPH trial arm to MASH, and early signals are promising. Novo Nordisk does not currently have equivalent MASH-specific Phase 3 data for CagriSema. For patients with fatty liver disease as a primary concern, retatrutide may prove to be the more targeted option.
Both drugs share a GLP-1 component, so the core GI side effect profile — nausea, vomiting, diarrhea, constipation — is similar in character, though the rates differ somewhat between the two.
Retatrutide's glucagon component introduces a mild tachycardia effect not seen with CagriSema — an average resting heart rate increase of approximately 5 BPM. This is something physicians will monitor but was not a significant cause of discontinuation in trials.
CagriSema's amylin component may offer a tolerability advantage in some patients — amylin's appetite suppression works through the brain's area postrema rather than the gut, potentially causing less GI disruption than pure GLP-1 escalation. Early Phase 3 data suggests a broadly comparable but not identical side effect profile to retatrutide.
CagriSema will almost certainly reach the market first, and Novo Nordisk's regulatory and commercial infrastructure gives it a real advantage in getting to patients quickly. If you are tracking the obesity drug space and want access to the next-generation option soonest, CagriSema is the near-term story.
Retatrutide, however, carries the more dramatic scientific proposition. The glucagon receptor adds a dimension — increased energy expenditure and direct liver fat metabolism — that CagriSema's amylin mechanism doesn't replicate. If the Phase 3 data holds anywhere near the Phase 2 results, retatrutide may ultimately be the stronger drug for weight loss and for metabolic disease more broadly.
The honest answer is that the obesity drug market is large enough for both. They will likely coexist as physicians match patients to the drug that fits their specific metabolic profile — just as Ozempic and Mounjaro coexist today serving different patients well.